Pediatric Lichen Planopilaris Treated With Pioglitazone
Pediatric lichen planopilaris (LPP) is a clinical variant of lichen planus (LP) that can lead to scarring hair loss without prompt intervention. While various therapies exist, intralesional and topical corticosteroids remain the mainstay of treatment in pediatric LPP. Refractory cases may require systemic therapies, selection of which may prove challenging due to the lack of data regarding pediatr …
Pediatric lichen planopilaris (LPP) is a clinical variant of lichen planus (LP) that can lead to scarring hair loss without prompt intervention. While various therapies exist, intralesional and topical corticosteroids remain the mainstay of treatment in pediatric LPP. Refractory cases may require systemic therapies, selection of which may prove challenging due to the lack of data regarding pediatr … Continue reading "Pediatric Lichen Planopilaris Treated With Pioglitazone"
On this Mnemonic Monday, we challenge you to remember the major diagnostic criteria for neurofibromatosis type I with the following mnemonic:
Chase Bank LOANS
C- Café-au-lait spots
B- Bony abnormalities (sphenoid wing dysplasia, pseudoarthrosis, sphenoid dysplasia, scoliosis)
L- Lisch nodules (iris hamartomas)
O-Optic glioma
A- Axillary/inguinal freckling (Crowe’s sign … 
With a special focus on patients with skin of color, the July issue of the Journal of Drugs in Dermatology is packed with outstanding articles, features, and case reports on topics ranging from OTC therapies for hair grow and choosing the right sunscreen in communities of color, to evaluation of a skin of color curriculum for dermatology residents and PLLA for correction of nasolabial folds. Stra … 
JDD authors Samuel S. Kassirer BA, Robert H. Gotkin MD, and Deborah S. Sarnoff MD present the first reported case of rhinophyma in a 62-year-old Fitzpatrick V female patient who was successfully treated with one session of fractional CO2 laser resurfacing. This case highlights the successful use of the fractional CO2 laser to treat rhinophyma in darker skin types (Fitzpatrick IV–VI) and undersco … 
INTRODUCTION
Palbociclib is one of three new small-molecule inhibitors of cyclin-dependent kinase 4 and 6 (CDK4/6) approved for use in the treatment of hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (Her2-) advanced or metastatic breast cancer. CDK4/6 inhibitors have a good overall safety profile but reported side effects include cytopenias, diarrhea, QTc pr … 